Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 11/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | IL6ST | P40189 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23927686 | 1.00 | PPARA (0.38) | PPARAIDH1MAPK1IL6STFAAH | |
| SCHEMBL23927680 | 1.00 | PPARA (0.38) | PPARAIDH1MAPK1IL6STFAAH | |
| SCHEMBL23927694 | 0.92 | FAAH (0.38) | PPARAIDH1MAPK1IL6STFAAH | |
| SCHEMBL30744169 | 0.92 | FAAH (0.38) | PPARAIDH1MAPK1IL6STFAAH | |
| SCHEMBL23927690 | 0.92 | FAAH (0.38) | PPARAIDH1MAPK1IL6STFAAH | |
| SCHEMBL23927693 | 0.92 | FAAH (0.38) | PPARAIDH1MAPK1IL6STFAAH | |
| SCHEMBL23522285 | 0.86 | PPARA (0.39) | PPARAIDH1MAPK1IL6STNAAA | |
| SCHEMBL30744181 | 0.86 | PPARA (0.39) | PPARAIDH1MAPK1IL6STNAAA | |
| SCHEMBL23501240 | 0.80 | IL6ST (0.41) | PPARAIDH1IL6STFAAHNAAA | |
| SCHEMBL23927598 | 0.80 | IL6ST (0.41) | PPARAIDH1IL6STFAAHNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | VIVAVISION (SHANGHAI) LTD (CN) | 2022-10-20 | — | — | US | disclosed |
| EP-3901156-A1 | NITROOXYDERIVATIVE OF ROCK KINASE INHIBITOR | Vivavision (Shanghai) Ltd (CN) | 2021-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332726-A1 | NITROXIDE DERIVATIVE OF ROCK KINASE INHIBITOR | ROCK1, NOS1, ROCK2 | PPARA 4561/4885IDH1 234/4885MAPK1 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.